Exalenz Of Israel, Pfizer Of U.S. In Deal With FDA-Approved Test Kit
This article was originally published in PharmAsia News
Executive Summary
Israel's Exalenz Bioscience has signed a replacement deal with U.S.-based Pfizer to use the BreathID noninvasive diagnostic kit to test Pfizer drugs for treating gastrointestinal disorders